Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine

Rollot, Florence; Nazal, Eve-Marie; Chauvelot-Moachon, Laurence; Kélaïdi, Charikleia; Daniel, Nathalie; Saba, Mona; Abad, Sebastien; Blanche, Philippe
December 2003
Clinical Infectious Diseases;12/15/2003, Vol. 37 Issue 12, p174
Academic Journal
Tenofovir-related tubular damage, like all other recently reported cases, occurred in patients receiving the protease inhibitor (PI) ritonavir, often with lopinavir. Increased plasma concentrations of didanosine were also observed after the addition of tenofovir. It was suspected that tenofovir with PIs interacted with renal organic anion transporters, leading to nephrotoxic tubular concentrations of tenofovir and systemic accumulation of didanosine. Until there is a better understanding of these interactions, close monitoring is recommended for patients receiving tenofovir, PIs, and didanosine.


Related Articles

  • HIV/AIDS Patients’ Perspectives on Adhering to Regimens Containing Protease Inhibitors. Stone, Valerie E.; Clarke, Jennifer; Lovell, Joan; Steger, Kathleen A.; Hirschhorn, Lisa R.; Boswell, Stephen; Monroe, Alicia D.; Stein, Michael D.; Tyree, Tamra J.; Mayer, Kenneth H.; Stone // JGIM: Journal of General Internal Medicine;Sep1998, Vol. 13 Issue 9, p586 

    OBJECTIVE: To gather qualitative data regarding HIV/AIDS patients’ perspectives about HIV-1 protease inhibitors (PIs), and about their experiences taking and adhering to regimens containing PIs. DESIGN: Six focus groups of persons under care for HIV were conducted between September and...

  • New AIDS survival rates mean patients returning to work. Minehan, Maureen // HR Magazine;Oct97, Vol. 42 Issue 10, p208 

    Reports that many patients are contemplating a return to work because of the success of protease inhibitors in reducing symptoms of Acquired Immune Deficiency Syndrome (AIDS). Questions that returnees have to answer before going back to work; Obligations of employers to employees and applicants...

  • CHILDREN HAVE NONADHERENCE PROBLEMS.  // AIDS Patient Care & STDs;Nov99, Vol. 13 Issue 11, p679 

    Examines the adherence of HIV perinatal-infected children who took a HAART regimen in Baltimore, Maryland. Inclusion of protease inhibitor in the regimen; Achievement and maintenance of undetectable viral loads; Publication of study in the Pediatric Infectious Disease Journal.

  • The aids vaccine controversy: A trial by 2000? D'Epiro, Nancy Walsh // Patient Care;1/15/1998, Vol. 32 Issue 1, p9 

    Reports on triple therapy with protease inhibitors which has been hailed widely as a breakthrough in acquired immune deficiency syndrome (AIDS) care. Information on 300 members of the International Association of Physicians in AIDS Care (IAPAC) volunteering to be subjects in a trial of a...

  • Venous Thrombosis Among Patients with AIDS. Majkif-Cruz, Abraham; Silva-Estrada, Mara; Sánchez-Barboza, Rita; Montiel-Manzano, Guadalupe; Treviño-Pérez, Sandra; Santoscoy-Gómez, Mario; de Chavez-Ochoa, Adriana Ruiz; Corona-de la Peña, Norma; Nieto-Cisneros, Leopoldo // Clinical & Applied Thrombosis/Hemostasis;Jan2004, Vol. 10 Issue 1, p19 

    Thrombosis has been considered an uncommon complication in patients with AIDS. In a 42-month period, 28 adult male homosexuals with AIDS experienced 34 thrombotic events. All but three received HAART regimen, two a successful round of double nucleoside analog therapy, and one patient received no...

  • Life, death, sex. Vilbig, Peter // Scholastic Update;10/20/97, Vol. 130 Issue 4, p10 

    Presents information on Acquired Immune Deficiency Syndrome (AIDS), focusing on drugs used in the treatment of the disease. Identification of Protease Inhibitors, a drug used to combat the virus; Discussion on whether these drugs should be provided free to patients; Information on the price of...

  • The new AIDS underclass. France, David // New York;12/09/96, Vol. 29 Issue 48, p32 

    Scrutinizes protease inhibitors, the most powerful drug to combat the AIDS virus as of December 1996. The number of people that the drug doesn't work for; The painful side effects of protease inhibitors; The experiences of Spencer Cox and Jules Levin with the drugs; The desire to find a cure...

  • Financial inhibitions. Gallagher, John // Advocate;09/16/97, Issue 742, p42 

    Focuses on a drug called the protease inhibitors for AIDS patients. Physiological effect on the body; Price of the protease inhibitor; Result of a missed dose of protease inhibitor on virus resistance.

  • AIDS groups to craft ways to fund new drugs. Breu, Joseph // Drug Topics;10/7/96, Vol. 140 Issue 19, p26 

    Reports on the funding crisis faced by various AIDS drug assistance programs (ADAPs) in the United States. Costs of adding protease inhibitors in their list of covered drugs; Efforts to develop proposals to increase funding source.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics